Brief: Mateon Therapeutics Inc Says First Patient Enrolled This Week In Its Phase IV Study
07/10/2020 12:43
Oct 7 (Reuters) - Mateon Therapeutics Inc MATN.PK :
* MATEON THERAPEUTICS INC - ANNOUNCED FIRST PATIENT ENROLLED
THIS
WEEK IN ITS PHASE IV STUDY ARTI-19
* MATEON THERAPEUTICS INC - TOP-LINE DATA FROM ARTI-19 IS
EXPECTED
BY END OF 4Q20
Source text for Eikon: ID:nGNX116xRC
Further company coverage: MATN.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncotelic Therapeutics
See all newsBrief: Oncotelic Therapeutics Emerging As Leader With New Independent JV Valuation
Brief: Oncotelic Therapeutics - JV Is Preparing For A Potential Initial Public Offering On The Hong Kong Stock Exchange In Late 2026
Brief: Oncotelic Therapeutics To Sell Its Necroptosis Cancer Therapy Assets To Mosaic Immunoengineering
Brief: Oncotelic Announces Initiation Of Clinical Study In Non-Small Lung Cell Cancer
Brief: Oncotelic Initiates Clinical Trials Evaluating Ot-101 Against Pediatric Gliomas